Deep Health AI India Ltd
Incorporated in 1993, Deep Diamond India Ltd is in the business of trading Diamond, Jewellery and Pharma products[1]
- Market Cap ₹ 30.8 Cr.
- Current Price ₹ 2.14
- High / Low ₹ 10.3 / 1.65
- Stock P/E 4.79
- Book Value ₹ 3.56
- Dividend Yield 4.67 %
- ROCE 19.8 %
- ROE 17.5 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Stock is trading at 0.60 times its book value
Cons
- Promoter holding is low: 0.03%
- Company has a low return on equity of 10.2% over last 3 years.
- Company has high debtors of 251 days.
- Working capital days have increased from 114 days to 332 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| 7.67 | 2.56 | 1.25 | 4.25 | |
| 6.08 | 2.82 | 0.79 | 1.08 | |
| Operating Profit | 1.59 | -0.26 | 0.46 | 3.17 |
| OPM % | 20.73% | -10.16% | 36.80% | 74.59% |
| 0.25 | 1.09 | 0.76 | -1.53 | |
| Interest | 0.10 | 0.26 | 0.09 | 0.03 |
| Depreciation | 0.01 | 0.01 | 0.01 | 0.01 |
| Profit before tax | 1.73 | 0.56 | 1.12 | 1.60 |
| Tax % | 27.75% | 25.00% | 21.43% | 28.75% |
| 1.26 | 0.42 | 0.88 | 1.13 | |
| EPS in Rs | 0.13 | 0.04 | 0.09 | 0.08 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -18% |
| TTM: | 240% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 72% |
| TTM: | 632% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 14% |
| 3 Years: | -34% |
| 1 Year: | -50% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 10% |
| Last Year: | 17% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 4.81 | 4.81 | 4.81 | 14.42 |
| Reserves | 9.92 | 15.61 | 17.55 | 36.95 |
| 0.00 | 1.66 | 0.61 | 0.37 | |
| 5.15 | 0.98 | 0.99 | 0.34 | |
| Total Liabilities | 19.88 | 23.06 | 23.96 | 52.08 |
| 4.47 | 4.46 | 4.45 | 0.01 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 3.54 | 5.59 | 32.82 |
| 15.41 | 15.06 | 13.92 | 19.25 | |
| Total Assets | 19.88 | 23.06 | 23.96 | 52.08 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| 0.55 | -5.43 | 0.19 | ||
| 0.29 | -2.23 | -0.23 | ||
| 0.00 | 5.01 | 0.00 | ||
| Net Cash Flow | 0.84 | -2.65 | -0.04 | |
| Free Cash Flow | 0.55 | -5.43 | 0.19 | |
| CFO/OP | 36% | 2,088% | 41% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor Days | 127.54 | 208.16 | 148.92 | 250.78 |
| Inventory Days | 86.55 | 264.73 | 1,241.00 | |
| Days Payable | 0.00 | 236.65 | 1,630.33 | |
| Cash Conversion Cycle | 214.09 | 236.24 | -240.41 | 250.78 |
| Working Capital Days | -60.91 | -27.09 | 37.96 | 331.51 |
| ROCE % | 4.35% | 5.37% | 19.81% |
Insights
In beta| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inventory Value INR Hundreds ・Standalone data |
|
|||||||||||
| Permanent Employee Count Number ・Standalone data |
||||||||||||
| Business Segment Focus - Pharmaceuticals Consultancy Binary (1=Active) ・Standalone data |
||||||||||||
| Associate and Subsidiary Entities Count ・Standalone data |
||||||||||||
| Manufacturing Facilities (Oasis Ceramics - Acquisition) Count ・Standalone data |
||||||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
31 May - A copy of the newspaper publication dated May 31, 2026, in the following newspapers with respect to Audited Standalone and Consolidated Financial Results for the …
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
31 May - A copy of the newspaper publication dated May 31, 2026, in the following newspapers with respect to Audited Standalone and Consolidated Financial Results for the …
-
Financial Results For The Quarter And Year Ended March 31, 2026
30 May - Board approved audited FY26 results on May 29; appointed internal auditor; auditor flagged Rs37.47 crore diversion.
-
Announcement under Regulation 30 (LODR)-Change in Management
29 May - Board approved FY26 audited standalone and consolidated results; appointed Valawat & Associates as internal auditor for FY27.
-
Board Meeting Outcome for Submission Of Revised Outcome Of Board Meeting In Compliance With The Regulation 30 Of The SEBI (LODR) Regulations 2015 (Listing Regulations).
29 May - Board approved audited FY2026 financial results and appointed M/s. Valawat & Associates as internal auditor.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1][2]
DDIL is engaged in the business of Rough & Polished Diamonds, sale, and trading of
diamond studded jewellery & Gold
Jewellery, and marketing of pharmaceutical goods and providing consultancy service
to the Pharmaceutical industry